Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HAT1 | O14929 | 2/20 | 0.48 |
| ▸ | EP300 | Q09472 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104090 | 0.83 | ALDH1A1 (0.58) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL27396427 | 0.82 | POLB (0.57) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL5539343 | 0.82 | POLB (0.57) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL17321400 | 0.80 | ALDH1A1 (0.61) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL29164608 | 0.78 | HTT (0.62) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL29965768 | 0.77 | POLB (0.72) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL535878 | 0.77 | POLB (0.72) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL10564241 | 0.76 | LMNA (0.59) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2434452 | 0.76 | POLB (0.70) | POLBNR4A2LMNAKMT2AALDH1A1 | |
| SCHEMBL15902357 | 0.76 | S1PR1 (0.45) | POLBLMNAKMT2AALDH1A1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-11414384-B2 | P300/CBP hat inhibitors | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3752250-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3752250-A1 | P300/CBP HAT INHIBITORS | Constellation Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| WO-2019161157-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMCEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019161157-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMCEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414384-B2 | P300/CBP hat inhibitors | EP300, HDAC1, KAT2A | POLB 1082/4885NR4A2 448/4885LMNA 1696/4885 |
| US-20210061762-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | POLB 1082/4885NR4A2 448/4885LMNA 1696/4885 |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | POLB 81/4885NR4A2 3844/4885LMNA 2214/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | POLB 81/4885NR4A2 3844/4885LMNA 2214/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | POLB 81/4885NR4A2 3844/4885LMNA 2214/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | POLB 81/4885NR4A2 3844/4885LMNA 2214/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | POLB 81/4885NR4A2 3844/4885LMNA 2214/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | POLB 81/4885NR4A2 3844/4885LMNA 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.